LAB Research completes research and development program that involves pulmonary monitoring system

New technology to improve interpretation of results and resource allocation during drug development process

LAB Research Inc. ("LAB" or "LAB Research"), (TSX: LRI), a Canadian-based global non-clinical contract research organization, today announced that it recently completed a research and development program that involves real time quantitative pulmonary monitoring of non-human primates using wireless telemetry technology. LAB consolidates its world leader position in safety pharmacology by being the first ever contract laboratory to conduct such a program.

The new system, qualified by the Canadian team of LAB Research, allows for simultaneous monitoring of cardiovascular and respiratory parameters in conscious freely moving animals. The numerous advantages of this new technology include enhanced interpretations of safety pharmacology results through correlation of cardiovascular and respiratory pharmacodynamics. This new system will provide potential improvements in resource allocation during the drug development process, as a result of the combination of cardiovascular and respiratory parameters in the same assessment. The new technology has completed the qualification phase and is expected to enter regulatory validation for eventual use in studies complying with Good Laboratory Practices (GLP) in early 2010.

"The completion of this world premiere research and development program is another solid proof of our commitment to excellence in drug development research," said Luc Mainville, President and Chief Executive Officer of LAB Research. "It also signals our continued efforts to validate novel laboratory systems that offer alternatives to or reduced reliance on the use of animals for research and development. The improvement in interpretation of safety pharmacology results and allocation of valuable resources during the drug development process will greatly benefit our clients while reducing the total number of animals used in such studies by 80%. Our goal is to have this new technology and its related benefits available to our clients early in 2010."